TriangleDISEASE & TREATMENT SETTING
Tecentriq: metastatic Urothelial carcinoma (neoadjuvant) after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Broader topic: Urothelial Carcinoma
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- neoadjuvant
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant t
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Tecentriq (atezolizumab) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
- source wording
- Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Study evidence for this setting
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Cabozantinib for Advanced Urothelial Cancer
A Study of TAS-120 in Patients With Advanced Solid Tumors
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated I
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice